Home »

Dr. Pradeep Garg

Pradeep Garg is the Executive Director of the Center for Molecular Imaging and Therapy (CMIT), a subsidiary of Biomedical Research Foundation of Northwest Louisiana, Shreveport, LA (BRF). Prior to joining BRF, Dr. Garg was Professor of Radiological Sciences at the Wake Forest University School of Medicine, Winston Salem, NC where he also directed the PET Research Center, a university-wide resource providing education, service, and research capabilities and opportunities. Prior to his tenure at Wake Forest, Dr. Garg was at Duke University Medical Center (1987-1995) and then moved to the Department of Radiology at Yale University Medical Center in New Haven, CT (1995-2003) where he later became the Director of the Yale University PET Center.

Dr. Garg is a molecular imaging scientist with research focus on the development and evaluation of novel radiopharmaceuticals as diagnostic and/or therapeutic agents. One of the major strengths Dr. Garg brings to the CMIT program is his ability to develop bench top research to products that directly benefit patients. He has been instrumental in carrying out several translational research projects over the years. His research efforts are concentrated in oncology, cardiology and neuroimaging. His laboratory has developed novel methods to incorporate bioactive functional groups and radionuclides into a variety of small molecules of biological interest, monoclonal antibodies, single chain proteins, peptides, and amino acids. As a molecular imaging principal investigator, he led multiple clinical trials that ranged from studying various imaging probes as possible tools to monitor therapeutic efficacy in patients, assessing the prognostic value of molecular imaging probes in patients with diseases such as prostate and esophageal cancer, and developed imaging probes to aid in the early diagnosis of Alzheimer disease. Previously his laboratory developed a PET analogue of MIBG for cardiac imaging which has shown clinical potential for imaging myocardial infarction and sympathetic innervation of the heart using PET. His group has been very active in developing imaging probes for a variety of neurological dysfunctions and has extensive work experience interrogating dopaminergic, serotonergic and norepinephrine systems. His research collaborators include basic science researchers, as well as clinicians and clinical researchers and he has been funded by a variety of sources including the NIH (R21, RO1, SBIR phase I and phase II), and the Department of Defense. In addition, he has an active research relationship and has funded projects from the pharmaceutical and biotech industry for translation research in non-human primates and in humans.
Dr. Garg has published more than seventy peer-reviewed papers in national and international journals and six book chapters. He served on numerous committees at his previous institutions and has served and continues to serve on numerous national and international committees. He is an active consultant on radiopharmaceuticals to the International Atomic Energy Agency (IAEA, Vienna) and is a member and leader of several professional organizations such as the Society of Nuclear Medicine and Molecular Imaging, Society of Molecular Imaging, Society of Radiopharmaceutical Sciences, Radiological Society of North America, American Chemical Society, and the American Association for Cancer Research. He served as Board member and as President of the Radiopharmaceutical Science Council of the Society of Nuclear Medicine and Molecular Imaging. He is chartered member of the medical imaging study section of the NIH and reviews grants for the SPORE, Quick Trials, program project grants, and other special emphasis panels of the NIH. He is on editorial board of several journals and is an active reviewer for a variety of national and international journals.